Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, shares toxicity data from the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.
Video Reports
Dr. Sznol Discusses the Combination of Ipilimumab and Nivolumab in Melanoma
Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the benefits of immunotherapy, specifically the combination of the CTLA-4 inhibitoripilimumab (Yervoy) and the PD-1 inhibitor nivolumab (Opdivo), in melanoma.
Neoadjuvant and Frontline Studies Guide Malignant Melanoma Treatment
The development of targeted therapies and immune checkpoint inhibitors has changed the management of malignant melanoma, providing safer and more effective treatment options and improving outcomes for many patients with this malignancy.
Dr. Flaherty on Second-Line Therapy for BRAF-Mutant Melanoma
Keith T. Flaherty, MD, professor of medicine, Harvard Medical School, director, Henri and Belinda Termeer Center for Targeted Therapy, director of clinical research, Massachusetts General Hospital, discusses treatment beyond frontline therapy for patients with BRAF-mutant relapsed/refractory melanoma.